Benlysta® (belimumab) is a targeted B-lymphocyte stimulator (BLyS)-specific inhibitor, designed for the management of systemic lupus erythematosus (SLE) in patients aged 5 years and older with active, autoantibody-positive disease, alongside standard therapy.
Indicated for adult patients with active lupus nephritis as part of a comprehensive treatment plan.
Each box contains 4 prefilled syringes of Benlysta® (belimumab) at a concentration of 200 mg/mL, meticulously formulated to offer a precise dosage and minimize preparation time.
Benlysta® injection is a clear to opalescent, colorless solution, ensuring ease of visual inspection before administration.
